Disease-associated microglia (DAM) represent a critical innate immune response in the Alzheimer's disease brain. These specialized microglia adopt a distinct transcriptional and functional phenotype in response to neurodegeneration, amyloid pathology, and tau pathology. Understanding DAM biology is essential for developing microglia-targeting therapeutic strategies for AD.
| Property | Value |
|---|---|
| Category | Innate Immune Cells |
| Location | Brain parenchyma, near amyloid plaques |
| Cell Type | Activated microglia |
| Key Receptors | TREM2, TLRs, CD33 |
| Discovery | 2019 (Keren-Shaul et al., Cell) |
Disease-associated microglia develop through a staged progression from homeostatic microglia to a fully activated disease-associated phenotype[1]:
| Feature | Description |
|---|---|
| Trigger | Microenvironmental signals (Aβ, neuronal injury) |
| Markers | Downregulation of P2ry12, Cx3cr1 |
| Function | Initial response, limited phagocytosis |
| TREM2 Status | TREM2-independent |
| Feature | Description |
|---|---|
| Trigger | Accumulation of Aβ and cellular debris |
| Markers | ApoE upregulation, lysosomal genes (Cst7, Cd68) |
| Function | Enhanced phagocytosis |
| TREM2 Status | TREM2-dependent activation |
| Feature | Description |
|---|---|
| Trigger | Chronic neurodegeneration |
| Markers | Type II interferon signature, complement proteins |
| Function | May become neurotoxic |
| TREM2 Status | TREM2-dependent |
| Gene | Function |
|---|---|
| APOE | Lipid metabolism, Aβ binding/clearance |
| CST7 | Lysosomal cysteine protease |
| CD68 | Phagocytic marker |
| TYROBP | TREM2 signaling adaptor |
| LPL | Lipoprotein lipase |
| CTSB/C | Cathepsins, lysosomal proteases |
| AXL | Tyrosine kinase receptor (clearance) |
| Gene | Function |
|---|---|
| P2RY12 | Homeostatic microglial marker |
| CX3CR1 | Fractalkine receptor |
| TMEM119 | Microglial membrane protein |
| SLC2A5 | Glucose transporter |
DAM play a complex role in amyloid pathophysiology:
Microglia contribute to tau spreading:
DAM produce pro-inflammatory mediators:
| Cytokine/Factor | Effect |
|---|---|
| IL-1β | Pro-inflammatory, promotes tau pathology |
| IL-6 | Acute phase response |
| TNF-α | Cytotoxic, promotes neuron loss |
| C1q | Complement-mediated synapse elimination |
| IL-10 | Anti-inflammatory (also upregulated) |
TREM2 is critical for DAM activation:
Aβ/Lipids → TREM2 → TYROBP → SYK → Microglial Activation
| Variant | Effect on DAM |
|---|---|
| R47H | ~3x AD risk, impaired Aβ phagocytosis |
| R62H | Moderate risk, partial impairment |
| H157Y | Impaired ligand binding |
| T96K | Loss of function |
DAM-like phenotypes appear in:
| Strategy | Approach | Status |
|---|---|---|
| TREM2 activation | AGO18, PY314 | Clinical trials |
| CSF1R inhibition | PLX5622 (in mice) | Preclinical |
| Anti-inflammatory | TNF inhibitors | Various stages |
| Complement inhibition | C1q, C3 blockers | Preclinical |
The study of Disease Associated Microglia In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.